Safety of treatment with biologics for psoriasis in daily practice: 5-year data by Van Lümig, PPM et al.
POSTER PRESENTATION Open Access
Safety of treatment with biologics for psoriasis in
daily practice: 5-year data
PPM Van Lümig
*, RJB Driessen, MAM Berends, J B Boezeman, PCM van de Kerkhof, EMGJ de Jong
From 5th European Workshop on Immune-Mediated Inflammatory Diseases
Sitges-Barcelona, Spain. 1-3 December 2010
Introduction
The safety of biological treatment for psoriasis is an
important issue. Concerns exist about a possible increased
risk of cancer, including nonmelanoma skin cancer
and lymphomas in psoriasis patients treated with TNF-a
inhibitors [1]. Dermatological conditions have been shown
to be a significant and clinically important problem in
rheumatoid arthritis patients receiving TNF-a blocking
therapy [2].
Aim
To prospectively evaluate the 5-year safety of biological
treatment for psoriasis in daily practice.
Patients and methods
A cohort of 173 psoriasis patients on biologics was pro-
spectively followed for 5 years [3]. All adverse events
reported were documented and analysed. Primary end-
point was the percentage of patients reporting at least
one serious adverse event. The rate of malignancies, ser-
ious infections and serious cardiovascular events was
compared to the general population incidence rate [4].
The nature and rate of dermatological adverse events
was compared with a group of prospectively followed
rheumatoid arthritis patients on TNF-a blocking ther-
apy [2].
Results
Between February 2005 and April 2010 173 patients were
enrolled in the registry and went through a total number
of 263 treatment episodes. The total number of patient
years of follow-up in the registry was 409. The number of
patient years was the highest for etanercept. Forty-nine
patients (28%) reported 88 serious adverse events. Only
one serious adverse event was certainly causally related to
the biologic and twenty-one events (24% of SAEs) were
considered possibly related. The incidence of malignan-
cies, serious infections and serious cardiovascular events
was comparable to the population incidence rate, except
for skin malignancies. The incidence of skin malignancies
was significantly higher than the general population inci-
dence rate. The nature and rate of dermatological adverse
events differed from the rheumatoid arthritis cohort.
Conclusion
In this cohort the safety of biological therapies for psoria-
sis was favorable with a low incidence of therapy-related
serious adverse events.
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